Replies to post #188790 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Journal of Translational Medicine
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6%20/

Among the ITT patients with a surgery date?≥?30 months prior to the data collection (n = 223), 30% (n = 67) have lived?≥?30 months, and their KM-derived mOS estimate is 46.5 months.

Sentiment,

I have a question.

Did just 67 live past 30 months? Or were 67 alive over 30 month at the time the data was taken for the journal?
And if 67 were alive at the time of the analysis why don’t we see 23 censors between month 30 and month 36? (67 – 44 = 23)

Journal of Translational Medicine

Among the ITT patients with a surgery date ≥ 36 months prior to the data collection (n = 182), 24.2% (n = 44) have lived ≥ 36 months and their KM-derived mOS estimate is 88.2 months.

[Leprecon7777]

"Long tail among ITT population
With immune-based therapies, a key focus is on the tail of the survival curve [26]. Among the ITT patients with a surgery date≥30 months prior to the data collection (n = 223), 30% (n = 67) have lived≥30 months, and their
KM-derived mOS estimate is 46.5 months. Among the ITT patients with a surgery date ≥ 36 months prior to the data collection (n = 182), 24.2% (n= 44) have lived ≥ 36 months and their KM-derived mOS estimate is
88.2 months."

I don't think there were more than 44 patients past 36 months based on my interpretation of the journal. As evidence consider that there should be 67-44=23 patients between 30 and 36 months.... Using your overall chart there were indeed a total of 23 sensors and events between 30 and 36 months.